KLOW Stack (GHK-Cu + TB-500 + BPC-157 + KPV) vs TB-500

KLOW Stack (GHK-Cu + TB-500 + BPC-157 + KPV)

This product is a blend of four research peptides, GHK-Cu, TB-500, BPC-157 and KPV, supplied together in one preparation. GHK-Cu is a copper-bound tripeptide first isolated from human plasma; TB-500 is the synthetic seven-residue fragment Ac-LKKTETQ from the actin-binding region of thymosin β4; BPC-157 is a 15-residue synthetic peptide derived from a sequence in a gastric juice protein; and KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone. Each component has been studied on its own, mostly in cell culture and animal models. No published work has examined the four in combination, and data on their chemical stability together are lacking, so the blend has no literature of its own.

TB-500

TB-500 is a synthetic seven-residue peptide, Ac-LKKTETQ, matching residues 17 to 23 of the 43-residue actin-binding protein thymosin β4. The stretch it copies lies in the central actin-binding region of thymosin β4; the N-terminal acetyl cap is a synthetic addition, since that position is internal in the native protein. The name is sometimes applied loosely to full-length thymosin β4, and the two should be kept apart: they differ in length, in mass (about 0.9 kDa against about 5 kDa) and in which parts of the parent protein they contain. Most published research concerns the full-length protein, examined in cell culture and in rodent models of skin, cardiac and corneal injury. Work on the fragment alone is far thinner, and it cannot be assumed to share the properties described for the whole protein.

How KLOW Stack (GHK-Cu + TB-500 + BPC-157 + KPV) acts

There is no described mechanism for the four-part blend, only separate observations on its components, made in separate models. GHK-Cu is a high-affinity copper complex that has been examined in fibroblast culture. TB-500 copies the central actin-binding motif of thymosin β4, a protein that sequesters monomeric actin. BPC-157 has been examined in rodent studies of nitric oxide and VEGF receptor signalling without a settled target. KPV has been reported in cell lines to lower NF-κB activation, possibly after uptake through the PepT1 transporter. No study has asked whether these peptides interact chemically or biologically when combined, so no joint action can be described.

How TB-500 acts

Full-length thymosin β4 binds monomeric G-actin in a one-to-one complex and is a major actin-sequestering protein in many cell types, holding actin in unpolymerised form. Structural studies place the LKKTET motif, shared with the WH2 family of actin-binding domains, at the centre of that contact, flanked by N-terminal and C-terminal segments that also touch actin. A small number of cell studies have reported that the isolated fragment affects endothelial cell migration, but how closely it reproduces the actin binding of the whole protein is not well established. Other activities attributed to thymosin β4 map elsewhere: the N-terminal tetrapeptide Ac-SDKP is released by enzymatic cleavage and has been studied separately.

The records side by side

• Type: KLOW Stack (GHK-Cu + TB-500 + BPC-157 + KPV), Four-peptide blend; TB-500, Heptapeptide (thymosin β4 fragment)
• Length: KLOW Stack (GHK-Cu + TB-500 + BPC-157 + KPV), not recorded; TB-500, 7 amino acids
• Molecular weight: KLOW Stack (GHK-Cu + TB-500 + BPC-157 + KPV), not recorded; TB-500, 889.0 g/mol
• Molecular formula: KLOW Stack (GHK-Cu + TB-500 + BPC-157 + KPV), not recorded; TB-500, C38H68N10O14

Reading a comparison

A comparison places two records side by side; it does not merge them. Each description above is drawn from that compound's own record, and the two were not necessarily characterised by the same methods, at the same time, or to the same level of detail. Before comparing any attribute, it is worth establishing that both records describe the substance you think they describe — names are not identifiers, and two entries sharing a name can differ in salt form, stereochemistry or the convention used to state a mass. Where a figure carries no method beside it, the comparison is between two reported numbers rather than between two measurements.